Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross- sectional study

摘要: Objective: The association betweenToxoplasma gondii seropositivity and respectively Bipolar Disorder (BD) Schizophrenia/Schizoaffective disorder (SZ) is one of the most studied link between pathogen psychiatric disorders. aim present study was thus to retrospectively determine if administrationofanantipsychoticand/oramoodstabilizerhavingknowninvitroAnti-ToxoplasmicActivity(TATAþ) wasassociatedwithabetterclinicaloutcomeinapopulationof152BDor114SZpatientsandseropositivefor T. infection compared patients receiving a treatment without anti-toxoplasmic activity (TATA-). Methods: This multicenter conducted in an academic public hospital during 3-years period 2009 2011. All consecutive inpatients outpatients with SZ or BD diagnosis stable for more than 4 weeks were recruited. socio-demographic clinical characteristics measured validated scales as well serological status toxoplasmic included. Treatments classified according their vitro antitoxoplasmic activity. A multivariate model used that significantly different no others. Results: positive serum antibodies against presented lifetime depressive episodes(p ¼0.048)afteradjustmentforage,sexandsociodemographiccharacteristicswhentreatedbydrug having anti-toxo activity, received drugs significant difference not found toxonegative toxopositive patients. Conclusions: It seems be importance consider prescribing drug clear (TATAþ) seropositive gondii, particular valproate mood stabilizer highest Prospective randomized controlled trials are warranted confirm this preliminary data.